The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

Condition	Treatment or Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine/naloxone	Phase II

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Please contact site for information.

Vermont
      Treatment Research Center, Burlington,  Vermont,  05401,  United States

Study chairs or principal investigators

Warren Bickel, Ph.D.,  Principal Investigator,  University of Vermont   

Study ID Numbers:  NIDA-06969-18; R01-06969-18
Record last reviewed:  December 2002
Last Updated:  November 18, 2004
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000236
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08